Jemperli savings card: as little as $0 a dose with commercial insurance

Jemperli is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Jemperli is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameJemperli

Authorized genericdostarlimab

Regular genericdostarlimab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Jemperli?

The original

–

Brand nameThe maker’s card

JEMPERLI Copay Program (Together with GSK)

Savings card from GSK

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a dose

See the offer on jemperli.com

In the maker’s words

“Eligible, commercially insured patients may pay as little as $0 for JEMPERLI.”

From the maker’s offer on jemperli.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Jemperli itself, from the same company, sold without the brand name, and usually for less. For now Jemperli is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Jemperli is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Endometrial (uterine) cancer
Advanced solid tumors with dMMR (mismatch repair deficient)

What the FDA label says

JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated:

Endometrial Cancer

in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).
as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

Mismatch Repair Deficient Recurrent or Advanced Solid Tumors

as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.1

1This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Jemperli (GlaxoSmithKline LLC), September 2, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/jemperli/